Imen Guizani1,2, Wiem Zidi1, Yosra Zayani1, Fourti Nesrine1, Hayet Douik3, Haifa Sanhaji1, Mohamed Sami Mourali4, Moncef Feki1, Monia Allal-Elasmi5,6. 1. LR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia. 2. Faculty of Mathematics, Physics and Natural Sciences, University of Tunis El Manar, Tunis, Tunisia. 3. LR99ES10 Human Genetics Laboratory, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. 4. Cardiology Department, CHU la Rabta, 1007, Jebbari Tunis, Tunisia. 5. LR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia. monia_elasmi@yahoo.fr. 6. Laboratory of Biochemistry, La Rabta Hospital, 1007, Jebbari, Tunis, Tunisia. monia_elasmi@yahoo.fr.
Abstract
BACKGROUND: Matrix metalloproteinases (MMPs) are widely expressed in atherosclerosis lesions. The disequilibrium of MMPs driving to an overexpression or a lack of its level can be influenced by genetic variations. MMP-3 and MMP-9 may be affected by specific polymorphisms like - 1612 5 A/6A and the - 1562 C/T respectively. We aim in the present study to investigate prospectively the association between the - 1612 5 A/6A MMP-3 and - 1562 C/T MMP-9 polymorphisms and clinical outcomes in patients with coronary artery disease (CAD). This study is elaborated to reveal whether one of these polymorphisms is a probable predictor of cardiovascular complications in this CAD cohort. METHODS AND RESULTS: A total of 168 patients with CAD were prospectively followed up over a period of 5 years. Genotypes for the MMP-3 (-1612 5 A/6A) and MMP-9 (-1562 C/T) polymorphisms were performed using PCR-RFLP. Their levels were measured by ELISA in Sandwich test during the follow-up period, 39 cardiovascular outcomes occurred with 21 repeat targets for revascularization, 3 patients with Myocardial infarction, 8 for heart failure, 5 for Stroke and 2 for cardiovascular mortality. The MMP-3 5 A/6A polymorphism was related to the disease on the contrary of the MMP-9 -1562 C/T. Patients carrying the 5 A allele had a higher level of MMP-3 level and those who carried the 6 A allele had lower level (p = 0.04). After applied multivariable Cox-hazard models we revealed that the 6 A allele is independently associated to the disease complication. Kaplan-Meier survival test revealed that individuals having the 6 A allele had a lower survival rate than those with the 5 A allele (p = 0.04). CONCLUSION: Our study suggests the disruption of the MMP-3 level may be due to the existence of the polymorphism - 1612 residing in its promoter region. MMP-3 can be considered as a marker of diagnosis and prediction in cardiovascular events.
BACKGROUND: Matrix metalloproteinases (MMPs) are widely expressed in atherosclerosis lesions. The disequilibrium of MMPs driving to an overexpression or a lack of its level can be influenced by genetic variations. MMP-3 and MMP-9 may be affected by specific polymorphisms like - 1612 5 A/6A and the - 1562 C/T respectively. We aim in the present study to investigate prospectively the association between the - 1612 5 A/6A MMP-3 and - 1562 C/T MMP-9 polymorphisms and clinical outcomes in patients with coronary artery disease (CAD). This study is elaborated to reveal whether one of these polymorphisms is a probable predictor of cardiovascular complications in this CAD cohort. METHODS AND RESULTS: A total of 168 patients with CAD were prospectively followed up over a period of 5 years. Genotypes for the MMP-3 (-1612 5 A/6A) and MMP-9 (-1562 C/T) polymorphisms were performed using PCR-RFLP. Their levels were measured by ELISA in Sandwich test during the follow-up period, 39 cardiovascular outcomes occurred with 21 repeat targets for revascularization, 3 patients with Myocardial infarction, 8 for heart failure, 5 for Stroke and 2 for cardiovascular mortality. The MMP-3 5 A/6A polymorphism was related to the disease on the contrary of the MMP-9 -1562 C/T. Patients carrying the 5 A allele had a higher level of MMP-3 level and those who carried the 6 A allele had lower level (p = 0.04). After applied multivariable Cox-hazard models we revealed that the 6 A allele is independently associated to the disease complication. Kaplan-Meier survival test revealed that individuals having the 6 A allele had a lower survival rate than those with the 5 A allele (p = 0.04). CONCLUSION: Our study suggests the disruption of the MMP-3 level may be due to the existence of the polymorphism - 1612 residing in its promoter region. MMP-3 can be considered as a marker of diagnosis and prediction in cardiovascular events.
Authors: A M Henney; P R Wakeley; M J Davies; K Foster; R Hembry; G Murphy; S Humphries Journal: Proc Natl Acad Sci U S A Date: 1991-09-15 Impact factor: 11.205
Authors: Zorina S Galis; Chad Johnson; Denis Godin; Richard Magid; J Michael Shipley; Robert M Senior; Eugen Ivan Journal: Circ Res Date: 2002-11-01 Impact factor: 17.367
Authors: B Zhang; S Ye; S M Herrmann; P Eriksson; M de Maat; A Evans; D Arveiler; G Luc; F Cambien; A Hamsten; H Watkins; A M Henney Journal: Circulation Date: 1999-04-13 Impact factor: 29.690
Authors: Barbara J Jefferis; Peter Whincup; Paul Welsh; Goya Wannamethee; Ann Rumley; Lucy Lennon; Andy Thomson; Debbie Lawlor; Claire Carson; Shah Ebrahim; Gordon Lowe Journal: Atherosclerosis Date: 2009-08-19 Impact factor: 5.162